N. C. DEMİRCAN Et Al. , "Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib," JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.5, pp.1147-1155, 2020
DEMİRCAN, N. C. Et Al. 2020. Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.5 , 1147-1155.
DEMİRCAN, N. C., Alan, O., Tuylu, T. B., Telli, T. A., Arikan, R., ÇİÇEK, F. C., ... Ercelep, O.(2020). Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib. JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.5, 1147-1155.
DEMİRCAN, NAZIM Et Al. "Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib," JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.5, 1147-1155, 2020
DEMİRCAN, NAZIM C. Et Al. "Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.5, pp.1147-1155, 2020
DEMİRCAN, N. C. Et Al. (2020) . "Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib." JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.5, pp.1147-1155.
@article{article, author={NAZIM CAN DEMİRCAN Et Al. }, title={Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib}, journal={JOURNAL OF ONCOLOGY PHARMACY PRACTICE}, year=2020, pages={1147-1155} }